热门资讯> 正文

CRISPR与Sirius Therapeutics合作开发Sirius疗法

2025-05-20 21:50

CRISPR Therapeutics (NASDAQ:CRSP) and Sirius Therapeutics have formed a partnership to jointly develop and commercialize small interfering RNA (siRNA) therapies.
The collaboration will initially focus on co-developing SRSD107, a siRNA therapy targeting factor XI for the treatment of thromboembolic disorders.
As part of the agreement, CRISPR Therapeutics will pay Sirius $25M in cash and invest $70M in equity.
CRISPR said it will also have the option to exclusively license up to two additional siRNA programs from Sirius in the future.

More on CRISPR Therapeutics

Crispr Therapeutics: Complex Casgevy Launch, But Broader Gene-Editing Potential Still Shines
CRISPR Therapeutics Struggles Under Slow Adoption And Regulatory Uncertainty (Downgrade)
Crispr Therapeutics Q1 Earnings Analysis: Ignore The Gloom, Stay The Course
Baby is given world's first personalized CRISPR therapy
SA analyst downgrades: VTRS, MRVL, MAR, NTR, CRSP, DB, VRSK, OCSL

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。